Endoscopic stomach procedure versus lifestyle program for weight regain after stopping GLP-1 medicines
Compares a stomach procedure plus lifestyle program with lifestyle alone in adults regaining weight.
Plain-language title generated from the registry record
Registry title: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07908823, who can take part
Where in China
- The Fifth medical center of Chinese PLA General HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Affiliated Hospital to Academy of Military Medical Sciences
- Trial code
- NCT07908823
- Record updated
- 2 November 2026
- Original description
This randomized controlled trial aims to evaluate the efficacy and safety of Endoscopic Radial Compression Gastroplasty (ERCG) in mitigating weight regain following discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approximately 60 adults with prior GLP-1 RA use and confirmed weight rebound after treatment cessation will be randomized 1:1 to either ERCG combined with Intensive Lifestyle Intervention (ILI), or ILI alone.Read full original descriptionShow less
Endoscopic Radial Compression Gastroplasty (ERCG) Versus Intensive Lifestyle Intervention (ILI) for Management of Weight Regain After Discontinuation of GLP-1 Receptor Agonists: An Open-Label Randomized Controlled Trial
This randomized controlled trial aims to evaluate the efficacy and safety of Endoscopic Radial Compression Gastroplasty (ERCG) in mitigating weight regain following discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approximately 60 adults with prior GLP-1 RA use and confirmed weight rebound after treatment cessation will be randomized 1:1 to either ERCG combined with Intensive Lifestyle Intervention (ILI), or ILI alone.
The primary outcome is the between-group difference in percent Total Body Weight Loss (%TBWL) from randomization to week 12; secondary outcomes include %TBWL at 24 and 52 weeks; changes in Body Mass Index (BMI), body composition, metabolic parameters (e.g., glycemic control, lipid profile), and quality of life; adherence to ILI; and adverse events, all assessed over 12, 24 and 52-week follow-up period. This study will generate preliminary evidence on the effectiveness and safety of ERCG as an intervention for weight regain after GLP-1 RA withdrawal, and the results will inform the design of future confirmatory trials, including sample size and endpoint selection.
Inclusion: Adults aged 18-65 years; Body mass index (BMI) ≥27.5 kg/m² at screening; Prior treatment with a GLP-1 receptor agonist (GLP-1 RA) for at least 12 weeks, with discontinuation more than 3 months before randomization; Documented weight regain of ≥3.0 kg after GLP-1 RA discontinuation; Adequate cardiopulmonary function and fitness for anesthesia and ERCG, as determined by clinical assessment; Willingness and ability to participate in the assigned intervention and complete 52 weeks of follow-up; Provision of written informed consent. Exclusion Criteria; Use of any GLP-1 RA or another medication prescribed for weight loss within three months before randomization; Previous bariatric surgery or endoscopic bariatric procedure; An untreated or inadequately controlled secondary cause of obesity; Upper gastrointestinal anatomy or disease that, in the investigator's judgment, would make ERCG unsafe or technically infeasible, including a hiatal hernia >3 cm, esophageal stricture, or active peptic ulcer disease; Clinically significant coagulopathy, including an international normalized ratio (INR) >1.5, or anticoagulant therapy that cannot be safely interrupted for the procedure; Pregnancy or breastfeeding.